EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter evaluation of the new MicroScan rapID/S plus antimicrobial susceptibility test System with gram-negative bacteria and selected cephems, penicillins beta-lactam/inhibitor combinations, and trimethoprim/sulfamethoxazole



Multicenter evaluation of the new MicroScan rapID/S plus antimicrobial susceptibility test System with gram-negative bacteria and selected cephems, penicillins beta-lactam/inhibitor combinations, and trimethoprim/sulfamethoxazole



Abstracts of the General Meeting of the American Society for Microbiology 102: 121



Background: The new MicroScan rapID/S plus AST System for gram-negative bacteria was evaluated in a multicenter study with fresh and stock clinical isolates. The new system combines early (4.5-5.5 h) MIC results with the capability to hold and read panels incrementally up to 18 h. Methods: The accuracy of the system with ampicillin, ampicillin/sulbactam (A/S), cefepime, cefuroxime, cephalothin, piperacillin, piperacillin/tazobactam (P/T), and trimethoprim/sulfamethoxazole (T/S) was evaluated at three sites by comparing the performance of the new system to an NCCLS broth microdilution reference panel. A combination of 444 fresh and 318 stock isolates was tested which included 581 Enterobacteriaceae, 134 Pseudomonas aeruginosa, 47 non-Enterobacteriaceae. Results: Essential agreement (+/- one doubling dilution) between the test system and the reference method ranged from 91.2% for piperacillin to 97.8% for ampicillin. Absolute categorical agreement based on interpretation ranged from 85.6% for A/S to 97.9% for T/S. Major error rates ranged from 0% (0/142) for cephalothin to 4% (14/351) for piperacillin. Because piperacillin and P/T have no intermediate category for P. aeruginosa even a 1 dilution difference can cause a major or very major error. For piperacillin, 3 of 14 major errors involved P. aeruginosa. Very major error rates were 0% (0/33) for cefepime, 0.3% (1/368) for ampicillin, 1.3% (3/223) for cefuroxime, 1.6% (4/243) for A/S, 2.1% (3/146) for piperacillin, 2.1% (7/341) for cephalothin, 3.6% (7/193) for T/S, and 6.2% (2/32) for P/T. T/S has no intermediate category and 5 of the 7 very major errors were one dilution errors. For P/T, 1 of the 2 very major errors was a one dilution error for P. aeruginosa. For all organisms, 52% of results were available by 4.5 hours with 87% available by 8 hours. Conclusion: This study showed that the new MicroScan rapID/S plus AST system for gram-negative bacteria correlates well with an NCCLS broth microdilution reference panel for the antimicrobials tested.

(PDF 0-2 workdays service: $29.90)

Accession: 035349831

Download citation: RISBibTeXText



Related references

Evaluation of the new MicroScan rapID/S plus antimicrobial susceptibility test system with gram-negative organisms with a challenge set and selected cephems, penicillins, beta-lactam/inihibitor combinations and trimethoprim/sulfamethoxazole. Abstracts of the General Meeting of the American Society for Microbiology 102: 121, 2002

Multicenter evaluation of the new MicroScan rapID/S plus Antimicrobial Susceptibility Test System with gram-negative bacteria and selected cephems. Abstracts of the General Meeting of the American Society for Microbiology 102: 121, 2002

Multicenter evaluation of the new MicroScan rapID/S plus antimicrobial susceptibility test system with gram-negative bacteria and fluoroquinolones. Abstracts of the General Meeting of the American Society for Microbiology 101: 203-204, 2001

Multicenter evaluation of the new MicroScan rapID/S plus Antimicrobial Susceptibility Test System with gram-negative bacteria and cephalothin, cefazolin, and nitrofurantoin. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 171, 2003

Evaluation of the new MicroScan rapID/S plus antimicrobial susceptibility test system for gram-negative organisms with a challenge set in a multicenter study. Abstracts of the General Meeting of the American Society for Microbiology 101: 204, 2001

Evaluation of the new MicroScan AST system for gram-negative bacteria with selected cephems and chloramphenicol. Abstracts of the General Meeting of the American Society for Microbiology 99: 122-123, 1999

Feasibility of the new MicroScan rapid AST system with aztreonam, aminoglycosides, selected cephems, quinolones, meropenem, nitrofurantoin and trimethoprim/sulfamethoxazole versus members of the family Enterobacteriaceae. Abstracts of the General Meeting of the American Society for Microbiology 99: 122, 1999

Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveillance Group. Diagnostic Microbiology and Infectious Disease 19(2): 111-120, 1994

Adapting MicroScan Rapid Gram-Negative Identification 3 system for use with the new MicroScan Antimicrobial Susceptibility Testing System. Abstracts of the General Meeting of the American Society for Microbiology 99: 197, 1999

Comparison of broth microdilution MICs and the Vitek System for determination of antimicrobial susceptibility of consecutively isolated and beta-lactam-resistant gram-negative bacilli to new and selected antimicrobial agents. Abstracts of the General Meeting of the American Society for Microbiology 94(0): 545, 1994

Multicenter evaluation of a new DNA microarray for rapid detection of clinically relevant bla genes from beta-lactam-resistant gram-negative bacteria. Antimicrobial Agents and ChemoTherapy 55(9): 4457-4460, 2012

Multicenter Evaluation of a New DNA Microarray for Rapid Detection of Clinically Relevant bla Genes from beta-Lactam-Resistant Gram-Negative Bacteria. 2011

Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria. Indian Journal of Medical Research 122(5): 425-428, 2006

Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against Gram negative bacteria. Indian Journal of Medical Research 122(5): 425-428, 2005

Preliminary evaluation of the new MicroScan AST system with beta-lactams, beta-lactam inhibitor combinations, and tetracycline versus members of the family Enterobacteriaceae. Abstracts of the General Meeting of the American Society for Microbiology 99: 157, 1999